Table 3.
Antibiotic sensitivity profiles for invasive GNRs causing bacteremia
| Percentage of isolates susceptible to each antibiotic (% (n/N)) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Total | Ampicillin/Sulbactam | Piperacillin/Tazobactam | Imipenem | Ceftazadime | Cefipime | Gentamicin | Amikacin | Tobramycin | Trim/Sulfa | |
| Klebsiella spp. | 164 | 47% (68/145) | 76% (125/164) | 96% (127/132) | 18% (29/157) | 96% (142/148) | 13% (15/120) | 55% (78/143) | 13% (15/118) | 86% (102/119) |
| Enterobacter spp. | 109 | 18% (12/67) | 75% (80/106) | 97% (57/59) | 34% (35/104) | 95% (89/94) | 32% (14/44) | 54% (50/93) | 28% (11/40) | 41% (17/41) |
| Pseudomonas aeruginosa | 55 | .00% (0/6) | 80% (44/55) | 31% (17/55) | 28% (15/54) | 81% (44/54) | 20% (11/54) | 18% (10/55) | 17% (9/54) | 9% (5/55) |
| Alcaligines faecalis | 29 | 25% (6/24) | 100% (26/26) | 96% (23/24) | 96% (25/26) | 15% (4/26) | 50% (4/8) | 25% (2/8) | 38% (3/8) | 100% (8/8) |
| Escherichia coli | 25 | 53% (9/17) | 100% (24/24) | 100% (9/9) | 48% (11/23) | 100% (18/18) | 50% (2/4) | 70% (14/20) | 50% (2/4) | 25% (1/4) |
| Pseudomonas other spp. | 20 | 0% (0/3) | 100% (20/20) | 75% (3/4) | 35% (7/20) | 100% (18/18) | 50% (3/6) | 61% (11/18) | 100% (3/3) | 67% (2/3) |
| Stenotrophomonas spp. | 11 | 0% (0/3) | 64% (7/11) | 27% (3/11) | 73% (8/11) | 64% (7/11) | 36% (4/11) | 27% (3/11) | 27% (3/11) | 100% (11/11) |
| Acinetobacter spp. | 8 | 100% (3/3) | 13% (1/8) | 38% (3/8) | 13% (1/8) | 13% (1/8) | 25% (2/8) | 14% (1/7) | 25% (2/8) | 25% (2/8) |
|
Proportion of isolates that would be sensitive to each antibiotic if used as empiric therapy | ||||||||||
| 0.37 | 0.79 | 0.80 | 0.33 | 0.86 | 0.33 | 0.48 | 0.20 | 0.59 | ||